|
|
|
|
|
|
|
24.04.26 - 19:09
|
Jane Street Made A Record $40 Billion In Trading Revenue Last Year, More Than All Wall Street Banks (ZeroHedge)
|
|
|
Jane Street Made A Record $40 Billion In Trading Revenue Last Year, More Than All Wall Street Banks
The 10am slam in bitcoin, which we documented virtually every days since 2024 may have ended once Jane Street got busted for insider trading in the Terraform collapse, but that doesn't mean that the Wall Street HFT trading giant slowed down. On the contrary: according to Bloomberg, Jane Street Group reeled in a Wall Street record $39.6 billion of trading revenue last year, more than any Wall Street bank.
According to the report, the firm beat out all global investment banks after reaping $15.5 billion in the year's final quarter, and with only 3,500 employees, it beat nearest rival JPMorgan by 11% during the year. The company's adjusted ETBIDA for the full year was a stunning $31.2 billion.
While Jane Street's profits were lifted by surging valuations of its stakes in privately held companies, the firm's main business matching buyers and sellers across assets thrived on bouts of market v...
|
|
|
24.04.26 - 19:09
|
U.S. Wheat Futs Hit Two-Year High As Wall Street Sounds Alarm Over Drought Shock (ZeroHedge)
|
|
|
U.S. Wheat Futs Hit Two-Year High As Wall Street Sounds Alarm Over Drought Shock
Hard red winter wheat climbed to a two-year high by the end of the week, as our coverage of the drought shock now hitting America's Breadbasket raises serious alarm bells on commodity desks.
The concern is not just reduced crop yields and quality. It is colliding with fertilizer shortages and elevated diesel prices, creating a broader inflationary transmission channel that could work its way through the food supply and translate into higher supermarket prices down the road.
Hard red winter wheat rose another 1% on Friday, with gains for the week approaching 6%. Active futures contracts in Chicago are now at their highest level since June 2024. Contracts are up 28% on the year.
On Thursday, UBS analysts, led by Jonathan Pingle, told clients that the drought conditions impacting the U.S. agricultural belt rank among the worst in more than 130 years:
The National Oceanic and Atmospheric Administration's Palmer Drou...
|
|
|
|
|
|
|
|
|
|
|
|
|
24.04.26 - 16:36
|
MÄRKTE USA/Intel-Kursfeuerwerk befeuert Technologieaktien (Dow Jones)
|
|
|
Von Steffen Gosenheimer DOW JONES--Im Spannungsfeld der weitgehend unverändert angespannten Lage im Nahen Osten und der Straße von Hormus und guten Geschäftszahlen geht es am Freitag im Frühhandel an der Wall Street mit den Indizes nach oben. Insbesondere ......
|
|
|
|
|
24.04.26 - 16:18
|
Stimmung der US-Verbraucher trübt sich im April ein (Dow Jones)
|
|
|
Die Stimmung der US-Verbraucher hat sich im April eingetrübt, wobei die Inflationserwartungen deutlich stiegen. Der an der Universität Michigan berechnete Index für die Verbraucherstimmung in den USA fiel bei der Umfrage am Monatsende auf 49,8 von 53,3 Ende März. Von Dow Jones Newswires befragte Ökonomen hatten einen Stand von 48,6 erwartet. Bei der ersten Umfrage Mitte des Monats lag er bei 47,6. Der Index für die Erwartungen belief sich auf 48,1 (Vormonat: 51,7, vorläufig: 46,1), der Index für die Einschätzung der aktuellen Lage wurde mit 52,5 (55,8 bzw. 50,1) angegeben.. --- Die Inflationserwartungen der Konsumenten auf Sicht von zwölf Monaten erhöhten sich auf 4,7 von 3,8 Prozent. Auf Sicht von fünf Jahren legten sie auf 3,5 von 3,2 Prozent zu..
|
|
|
|
|
|
|
24.04.26 - 16:06
|
Börsenwoche: Warum US-Aktien so gut laufen (FAZ)
|
|
|
Die Inflationsgefahr steigt, der Irankrieg dauert an – und der US-Leitindex S&P 500 erreicht einen Höchststand. Ist das fundamental gerechtfertigt, oder blenden Anleger Risiken aus?...
|
|
|
24.04.26 - 15:39
|
Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street (ZeroHedge)
|
|
|
Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street
Shares of Eli Lilly & Co. fell in New York premarket trading after new industry prescription data for the drugmaker's blockbuster obesity shot Zepbound and recently approved oral weight-loss pill Foundayo disappointed Wall Street analysts.
Foundayo generated 3,707 prescriptions in its second week, according to new prescription-tracking data from IQVIA cited by RBC Capital Markets analysts. That compares with 18,410 prescriptions for Novo's oral version of Wegovy during its second week after launch, suggesting Lilly's weight-loss drugs are falling behind in the GLP-1 race.
"While we believe comparisons early into launch should be considered immaterial, Foundayo's uptake this week is likely to be received negatively," RBC Capital Markets analyst Trung Huynh wrote in a note to clients earlier.
In a separate note citing the IQVIA data, Cantor analyst Carter Gould said, "We see slower TRx (total prescriptions) growth ...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
